Leo Wealth LLC Purchases New Shares in GSK PLC Sponsored ADR $GSK

Leo Wealth LLC purchased a new stake in GSK PLC Sponsored ADR (NYSE:GSK) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 18,816 shares of the pharmaceutical company’s stock, valued at approximately $906,000.

Other institutional investors have also recently bought and sold shares of the company. Mondrian Investment Partners LTD raised its position in shares of GSK by 1.1% during the third quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company’s stock worth $239,210,000 after acquiring an additional 55,116 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of GSK by 842.9% during the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after acquiring an additional 852,437 shares during the period. Foster Victor Wealth Advisors LLC lifted its stake in shares of GSK by 5.8% during the third quarter. Foster Victor Wealth Advisors LLC now owns 438,220 shares of the pharmaceutical company’s stock valued at $21,674,000 after acquiring an additional 23,934 shares during the period. Sound Income Strategies LLC lifted its stake in shares of GSK by 2.7% during the third quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company’s stock valued at $16,209,000 after acquiring an additional 9,218 shares during the period. Finally, Waverly Advisors LLC boosted its holdings in GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after acquiring an additional 270,863 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

GSK stock opened at $51.10 on Tuesday. The business’s fifty day moving average is $49.58 and its 200-day moving average is $52.36. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The company has a market cap of $103.37 billion, a P/E ratio of 15.98, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33. GSK PLC Sponsored ADR has a twelve month low of $42.88 and a twelve month high of $61.69.

GSK (NYSE:GSK) last posted its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same period last year, the company earned $0.47 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. Equities research analysts forecast that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on GSK shares. Berenberg Bank reiterated a “buy” rating on shares of GSK in a research report on Tuesday, October 6th. Weiss Ratings downgraded shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Jefferies Financial Group restated a “buy” rating on shares of GSK in a research report on Monday, September 28th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Finally, Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, GSK currently has an average rating of “Hold” and an average price target of $55.33.

GSK Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.